CLAIMS

1. A vascular endothelial growth factor (VEGF) variant, characterized in that at least one amino acid in the sequence of the native vascular endothelial growth factor at positions 109 to 112 of the native vascular endothelial growth factor is replaced by another amino acid or a deletion.

2. The VEGF variant according to claim 1, characterized in that at least one amino acid in the sequence of the native vascular endothelial growth factor at positions 109 to 112 is replaced by proline.

3. The VEGF variant according to claim 2, characterized in that, besides proline, at least one further amino acid at one of the positions 109 to 112 is replaced or is a deletion.

4. The VEGF variant according to claim 1, characterized in that the alanine at AA position 111 of the native vascular endothelial growth factor is replaced by proline.

5. The VEGF variant according to claim 4, characterized in that the arginine at AA position 110 of the native vascular endothelial growth factor is replaced by another amino acid.

6. The VEGF variant according to claim 1, characterized in that the arginine at AA position 110 of the native vascular endothelial growth factor is replaced by proline.

7. The VEGF variant according to claim 6, characterized in that the alanine at AA position 111 of the native vascular endothelial growth factor is replaced by another amino acid.

8. The VEGF variant according to claims 4 to 7, characterized in that the arginine at AA position 110 of the native vascular endothelial growth factor

and the alanine at AA position 111 of the native vascular endothelial growth factor are replaced by proline.

9. The VEGF variant according to any of claims 1 to 8, where the VEGF variant is in the form of any of the splice variants $VEGF_{121}$, $VEGF_{145}$, $VEGF_{165}$, $VEGF_{183}$, $VEGF_{189}$ or $VEGF_{206}$.

10. The $VEGF_{165}$ variant according to any of claims 1 to 8, characterized in that it has one of the amino acid sequences

Seq. No. 1:

Ala Pro Met Ala Glu Gly Gly Gly Gln Asn His His Glu Val Val Lys Phe Met Asp Val Tyr Gln Arg Ser Tyr Cys His Pro Ile Glu Thr Leu Val Asp Ile Phe Gln Glu Tyr Pro Asp Glu Ile Glu Tyr Ile Phe Lys Pro Ser Cys Val Pro Leu Met Arg Cys Gly Gly Cys Cys Asn Asp Glu Gly Leu Glu Cys Val Pro Thr Glu Glu Ser Asn Ile Thr Met Gln Ile Met Arg Ile Lys Pro His Gln Gly Gln His Ile Gly Glu Met Ser Phe Leu Gln His Asn Lys Cys Glu Cys Arg Pro Lys Lys Asp Arg Pro Arg Gln Glu Asn Pro Cys Gly Pro Cys Ser Glu Arg Arg Lys His Leu Phe Val Gln Asp Pro Gln Thr Cys Lys Cys Ser Cys Lys Asn Thr Asp Ser Arg Cys Lys Ala Arg Gln Leu Glu Leu Asn Glu Arg Thr Cys Arg Cys Asp Lys Pro Arg Arg

or Seq. No. 2:

Ala Pro Met Ala Glu Gly Gly Gly Gln Asn His His Glu Val Val Lys Phe Met Asp Val Tyr Gln Arg Ser Tyr Cys His Pro Ile Glu Thr Leu Val Asp Ile Phe Gln Glu Tyr Pro Asp Glu Ile Glu Tyr Ile Phe Lys Pro Ser Cys Val Pro Leu Met Arg Cys Gly Gly Cys Cys Asn Asp Glu Gly Leu Glu Cys Val Pro Thr Glu Glu Ser Asn Ile Thr Met Gln Ile Met Arg Ile Lys Pro His Gln Gly Gln His Ile Gly Glu Met Ser Phe Leu Gln His Asn Lys Cys Glu Cys Arg Pro Lys Lys Asp Lys Pro Arg Gln Glu Asn Pro Cys Gly Pro Cys Ser Glu Arg Arg Lys His Leu Phe Val Gln Asp Pro Gln Thr Cys Lys Cys Ser Cys Lys Asn Thr Asp Ser Arg Cys Lys Ala Arg Gln Leu Glu Leu Asn Glu Arg Thr Cys Arg Cys Asp Lys Pro Arg Arg.

11. The VEGF variant according to any of claims 1 to 8, characterized in that the amino acid chain is modified or derivatized and/or comprises mutations, insertions and/or deletions and/or in that it has a signal sequence.

12. The VEGF variant according to claim 11, characterized in that the signal sequence is connected N-terminally to the amino acid chain of the VEGF variant and has the sequence

Met Asn Phe Leu Ser Trp Ser Val His Trp Ser Leu Ala Leu Leu Leu Tyr Leu His His Ala Lys Trp Ser Gln Ala.

13. Nucleic acids coding for VEGF variants according to any of claims 1 to 12.

14. Vectors comprising nucleic acids according to claim 13 for the expression of VEGF variants according to any of claims 1 to 12.

15. A medicament comprising VEGF variants according to any of claims 1 to 12, nucleic acids according to claim 13 or vectors according to claim 14.

16. The use of VEGF variants according to any of claims 1 to 12, of nucleic acids according to claim 13 or of vectors according to claim 14 for producing a

medicament for the treatment of chronic wounds, especially caused by vascular lesions, such as chronic venous insufficiency (CVI), primary/secondary lymphoedema, arterial occlusive disease, metabolic disorders, such as diabetes mellitus, gout or decubitus ulcer, chronic inflammatory disorders, such as pyoderma gangrenosum, vasculitis, perforating dermatoses, such as diabetic necrobiosis lipoidica and granuloma annulare, haematological primary disorders such as coagulation defects, sickle-cell anaemia and polycythemia vera, tumours, such as primary cutaneous tumours and ulcerative metastases, for plasmin inhibition, for the induction of neoangiogenesis, and/or for the inhibition of matrix degradation.